HC Wainwright Raises Earnings Estimates for Cytokinetics

Posted by on Aug 11th, 2026

Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – Analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Cytokinetics in a report released on Friday, August 7th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will post earnings per share of ($1.65) for the quarter, up from their prior estimate of ($1.80). HC Wainwright currently has a “Buy” rating and a $140.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($6.20) per share. HC Wainwright also issued estimates for Cytokinetics’ Q4 2026 earnings at ($1.55) EPS and FY2026 earnings at ($6.38) EPS.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.13. The business had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. During the same quarter last year, the company posted ($1.12) earnings per share. The company’s revenue was down 57.1% on a year-over-year basis.

Several other research analysts have also recently commented on CYTK. JPMorgan Chase & Co. raised their target price on shares of Cytokinetics from $92.00 to $97.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Stifel Nicolaus increased their target price on Cytokinetics from $98.00 to $108.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Truist Financial raised their target price on shares of Cytokinetics from $106.00 to $112.00 and gave the company a “buy” rating in a report on Monday. UBS Group upgraded shares of Cytokinetics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $69.00 to $115.00 in a research report on Monday, June 29th. Finally, Wall Street Zen downgraded shares of Cytokinetics from a “hold” rating to a “sell” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Cytokinetics presently has an average rating of “Moderate Buy” and an average price target of $101.15.

Get Our Latest Stock Report on Cytokinetics

Cytokinetics Stock Up 1.0%

NASDAQ CYTK opened at $77.49 on Tuesday. The firm has a 50-day moving average price of $78.99 and a two-hundred day moving average price of $71.05. Cytokinetics has a 12-month low of $32.89 and a 12-month high of $88.31. The company has a market capitalization of $9.64 billion, a P/E ratio of -10.73 and a beta of 0.39.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Cytokinetics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock worth $765,538,000 after acquiring an additional 191,336 shares during the period. Royce & Associates LP raised its holdings in Cytokinetics by 44.3% during the 4th quarter. Royce & Associates LP now owns 144,426 shares of the biopharmaceutical company’s stock worth $9,177,000 after purchasing an additional 44,343 shares during the last quarter. Norges Bank acquired a new position in shares of Cytokinetics in the 4th quarter worth approximately $51,281,000. GW&K Investment Management LLC lifted its position in shares of Cytokinetics by 161.5% in the 4th quarter. GW&K Investment Management LLC now owns 472,363 shares of the biopharmaceutical company’s stock worth $30,015,000 after purchasing an additional 291,693 shares during the period. Finally, Eventide Asset Management LLC boosted its stake in shares of Cytokinetics by 181.9% in the 4th quarter. Eventide Asset Management LLC now owns 479,611 shares of the biopharmaceutical company’s stock valued at $30,473,000 after purchasing an additional 309,503 shares during the last quarter.

Insider Transactions at Cytokinetics

In related news, EVP Andrew Callos sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $74.08, for a total transaction of $1,111,200.00. Following the completion of the transaction, the executive vice president directly owned 58,555 shares in the company, valued at $4,337,754.40. This represents a 20.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $84.92, for a total transaction of $636,900.00. Following the transaction, the chief executive officer owned 377,830 shares of the company’s stock, valued at approximately $32,085,323.60. This represents a 1.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 122,679 shares of company stock valued at $9,701,754 in the last three months. Company insiders own 2.60% of the company’s stock.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

  • Positive Sentiment: HC Wainwright raised its 2026 earnings estimates, reducing its projected losses to $1.65 per share for the third quarter, $1.55 for the fourth quarter and $6.38 for full-year 2026. The firm maintained a “Buy” rating and a $140 price target, implying substantial upside from recent trading levels.
  • Positive Sentiment: Several analysts have recently increased their valuation targets for CYTK, including Citizens JMP at $110 and Truist Financial at $112. The broader analyst consensus remains a “Moderate Buy,” with an average price target of approximately $101.15. Cytokinetics Price Target Raised to $110 Cytokinetics Price Target Raised to $112
  • Positive Sentiment: The estimate revisions follow Cytokinetics’ recent quarterly results, in which it reported a smaller-than-expected loss and revenue above consensus forecasts. Those results may be reinforcing confidence in the company’s pipeline and future growth prospects.
  • Neutral Sentiment: CEO Robert Blum sold 7,500 shares for approximately $575,700 at an average price of $76.76. The transaction was executed under a pre-arranged Rule 10b5-1 plan, leaving him with 377,820 shares; therefore, it appears less concerning than an unexpected discretionary sale. Insider Selling: Cytokinetics CEO Sells 7,500 Shares

Cytokinetics Company Profile

(Get Free Report)

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

Featured Stories

Earnings History and Estimates for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.